动态胸苷激酶活性独立反映内分泌耐药HR+/HER2-转移性乳腺癌的治疗特异性生物学反应并与结局独立相关
本研究为III期GEICAM/2013-02 PEARL试验的转化分析,纳入555例内分泌耐药HR+/HER2-转移性乳腺癌患者,采用FDA认证的标准化方法检测血浆胸苷激酶1活性(TKa)。结果显示基线低TKa(≤250 DuA)与更长的无进展生存期和总生存期独立相关,但不区分两治疗臂获益;治疗早期TKa动态变化可提供治疗特异性信息,支持用于疗效监测。
要点
- 基线TKa≤250 DuA与更长PFS和OS独立相关,且不受治疗方式影响。
- 基线TKa无法区分内分泌治疗联合哌柏西利与卡培他滨两臂的获益差异。
- 治疗早期TKa动态变化具有治疗特异性,可反映两药作用机制差异并支持疗效监测。
核心结论
- 基线TKa是强预后指标,早期动态变化提供额外的治疗特异性信息,支持用于反应监测。
研究设计与样本
- III期GEICAM/2013-02 PEARL试验的转化分析,比较内分泌治疗联合哌柏西利与卡培他滨。
- 采用FDA认证的标准化方法分析555例患者的血浆TKa。
- 基线以预设阈值250 DuA区分低与高增殖活性,并探索其他阈值用于治疗交互和治疗中监测。
主要发现
- 基线低TKa(≤250 DuA)在多变量分析中与更长PFS(11.4 vs 4.0个月)和OS(38.5 vs 17.3个月)独立相关,且不受治疗影响。
- 基线TKa未能区分两治疗臂的获益。
- 第1周期第15天,卡培他滨组中位TKa高于内分泌治疗联合哌柏西利组(448 vs 28 DuA)。
- 卡培他滨臂中,TKa早期升高超过2倍与改善的PFS和OS独立相关。
- 内分泌治疗联合哌柏西利期间TKa持续升高(>50 DuA)提示结局较差,与基线水平无关。
关键数值与推荐
- 基线低增殖活性预设阈值为TKa≤250 DuA。
- 第1周期第15天中位TKa:卡培他滨448 DuA,内分泌治疗联合哌柏西利28 DuA。
- 卡培他滨臂TKa早期升高>2倍与改善PFS和OS独立相关。
- 内分泌治疗联合哌柏西利期间TKa持续>50 DuA提示结局较差。
临床怎么用
- 基线TKa可用于HR+/HER2-转移性乳腺癌的预后分层。
- 治疗早期动态监测TKa有助于评估治疗特异性生物学反应。
- 卡培他滨治疗中TKa早期升高>2倍或提示较好结局,哌柏西利联合内分泌治疗中TKa持续>50 DuA提示需关注不良结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment selection in endocrine-resistant HR+ /HER2 - metastatic breast cancer (MBC) remains challenging, and early predictive biomarkers are lacking. Circulating thymidine kinase 1 activity (TKa) is a blood-based proliferation marker suitable for dynamic monitoring. METHODS: This translational study was conducted within the phase III GEICAM/2013-02 PEARL trial comparing endocrine therapy (ET) plus palbociclib versus capecitabine in HR+ /HER2 - MBC. Plasma from 555 patients was analyzed using a standardized FDA-cleared assay. TKa was assessed at baseline using a prespecified cutoff of 250 DuA to define low versus high proliferative activity, and additional thresholds were explored for treatment interaction and on-treatment monitoring. Associations with progression-free survival (PFS) and overall survival (OS) were evaluated using multivariable Cox models. RESULTS: Low baseline TKa (≤250 DuA) was independently associated with longer PFS (11.4 vs 4.0 months) and OS (38.5 vs 17.3 months), in multivariate analysis and irrespective of treatment. However, baseline TKa did not discriminate benefit between arms. Early on-treatment TKa dynamics provided treatment-specific information. At cycle 1 day 15, median TKa was higher with capecitabine than with ET plus palbociclib (448 vs 28 DuA), consistent with distinct mechanisms. In the capecitabine arm, a > 2-fold early increase in TKa was independently associated with improved PFS and OS. Conversely, persistently elevated TKa (>50 DuA) during ET plus palbociclib identified patients with poorer outcomes, regardless of baseline levels. CONCLUSIONS: Baseline TKa is strongly prognostic, while early dynamic changes provide additional, treatment-specific information, reflecting differences in mechanism of action between therapies, that support response monitoring.
引用
- Guerrero-Zotano Á, Gil-Gil M, Williams A, et al. Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial. Eur J Cancer. 2026. PMID: 42202479. doi:10.1016/j.ejca.2026.116817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。